COX6C encodes a structural subunit of cytochrome c oxidase (Complex IV), the final enzyme in the mitochondrial electron transport chain, which is essential for efficient ATP production and cellular energy metabolism.
While not directly involved in electron transfer, COX6C plays a key role in stabilizing Complex IV, regulating oxidative phosphorylation, and influencing mitochondrial function across various tissues, with implications for metabolic disorders, neurodegenerative diseases, and cancer.
The COX6C gene encodes cytochrome c oxidase subunit 6C, a nuclear-encoded component of cytochrome c oxidase (COX, Complex IV), the terminal enzyme of the mitochondrial electron transport chain (ETC).
COX is responsible for transferring electrons from cytochrome c to molecular oxygen, generating the proton gradient that drives ATP synthesis through oxidative phosphorylation (OXPHOS).
While COX6C is not directly involved in electron transfer, it plays an essential structural and regulatory role within Complex IV by:
COX6C is broadly expressed across tissues but is particularly abundant in organs with high energy demands, such as:
It is localized to the inner mitochondrial membrane, where it integrates into the COX complex and modulates cellular energy metabolism.
Altered COX6C expression or mutations can contribute to mitochondrial dysfunction, impacting multiple organ systems and increasing disease susceptibility.
Although COX6C mutations are less well-characterized than other mitochondrial proteins, some research demonstrates their role in cancer, metabolic disorders, and neurodegenerative diseases.
COX6C dysfunction affects oxidative phosphorylation and mitochondrial energy production, contributing to metabolic diseases.
COX6C mRNA is downregulated in end-stage renal disease (ESRD), increasing oxidative stress and mitochondrial dysfunction. Targeting COX6C pathways may improve renal function.
COX6C is reduced in insulin-resistant individuals, linking mitochondrial dysfunction to glucose metabolism impairment. In contrast, in insulin-sensitive individuals, COX6C is normally upregulated after exercise.
In diabetic nephropathy (DN), COX6C is elevated in renal cells, potentially worsening dysfunction.
Interventions targeting COX6C could improve mitochondrial efficiency in diabetes.
COX6C plays a role in vascular damage via oxidative phosphorylation dysfunction, contributing to atherosclerosis and cardiovascular disease.
COX6C dysfunction contributes to neuronal energy deficits and neurodegeneration. Because of its connection to brain function, COX6C may serve as a biomarker for neurodegeneration and a target for neuroprotective therapies.
Reduced COX6C disrupts mitochondrial metabolism, implicated in worsening neurodegeneration.
Impaired COX6C function causes neuronal energy failure, making it a potential stroke recovery target.
COX6C dysregulation in skeletal muscle contributes to muscle degeneration and mitochondrial inefficiency, potentially hastening disease progression.
Beyond metabolism, COX6C regulates apoptosis and immune responses. Because of this, COX6C markers could aid in cancer prognosis, while targeting COX6C pathways may benefit HIV-associated mitochondrial dysfunction.
COX6C is released during intrinsic apoptotic signaling, and elevated levels in tumors may inhibit apoptosis, promoting cancer survival.
It may also promote cancer growth by increasing ATP production in cancerous cells. For example, increased COX6C overexpression due to KRAS mutations in pancreatic cancer enhances mitochondrial ATP production and oxidative phosphorylation, promoting tumor cell survival and proliferation.
COX6C is frequently amplified in lung adenocarcinoma (LUAD), located at chromosome 8q22.2, and its overexpression correlates with increased tumor cell proliferation and worse prognosis.
Given its role in metabolic reprogramming, COX6C may serve as a prognostic biomarker and potential therapeutic target for certain cancers.
The following section outlines the testing procedures and interpretation.
Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types.
A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.
Normal reference ranges for COX6C genetic testing are considered to be without mutations that can alter the activity of the COX6C proteins.
The clinical implications of a positive COX6C mutation test result will vary by individual, although COX6C mutations in symptomatic patients may signal a need for further assessment and possibly treatment, especially in the setting of various symptoms.
Patients or practitioners with questions about the clinical implications of COX6C mutations should seek further assessment with a genetic counselor or expert.
Click here to compare genetic test panels and order genetic testing for health-related SNPs.
COX6C cytochrome c oxidase subunit 6C [Homo sapiens (human)] - Gene - NCBI. (2025). Nih.gov. https://www.ncbi.nlm.nih.gov/gene/1345
Kadenbach, B. (2020). Complex IV– the regulatory center of mitochondrial oxidative phosphorylation. Mitochondrion. https://doi.org/10.1016/j.mito.2020.10.004
Liu, S., Shao, F., Wang, Y. et al. COX6C expression driven by copy amplification of 8q22.2 regulates cell proliferation via mediation of mitosis by ROS-AMPK signaling in lung adenocarcinoma. Cell Death Dis 15, 74 (2024). https://doi.org/10.1038/s41419-024-06443-w
Tian BX, Sun W, Wang SH, Liu PJ, Wang YC. Differential expression and clinical significance of COX6C in human diseases. Am J Transl Res. 2021 Jan 15;13(1):1-10. PMID: 33527004; PMCID: PMC7847502.
Wang, C., Lv, J., Xue, C. et al. Novel role of COX6c in the regulation of oxidative phosphorylation and diseases. Cell Death Discov. 8, 336 (2022). https://doi.org/10.1038/s41420-022-01130-1
Yang, J., Liu, J., Zhang, S., Yang, Y., & Gong, J. (2018). The overexpression of cytochrome c oxidase subunit 6C activated by Kras mutation is related to energy metabolism in pancreatic cancer. Translational Cancer Research, 7(2), 290–300. https://doi.org/10.21037/tcr.2018.03.02